Efficacy and tolerance of interferon-α in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis

Liver International

Volumn 26, Issue 3, 2006, Pages 305-310

  Rocha, Cristina M ^a   Perez, Renata M ^a   Ferreira, Adalgisa P ^a   Carvalho Filho, Roberto J ^a   Pace, Fabio H ^a   Silva, Ivonete S ^a   Pestana, José O M ^a   Lanzoni, V P Valeria P ^a   Silva, Antonio E ^a   Ferraz, Maria Lucia Gomes ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

End stage renal disease; Hemodialysis; Hepatitis C; Interferon ; Liver; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BONE MARROW DEPRESSION; BONE PAIN; CEREBROVASCULAR ACCIDENT; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION COMPLICATION; KIDNEY FAILURE; LIVER BIOPSY; LIVER FAILURE; MALE; MONOTHERAPY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PNEUMONIA; SKIN DISEASE; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33644796882     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01225.x     Document Type: Article

References (31)

1. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11 (10): 1896-902.
2. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74 (4): 427-437
3. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36 (1): 3-10.
4. Hanafusa T, Ichikawa Y, Yazawa K, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66 (4): 471-6.
5. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29 (1): 257-63.
6. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001; 8 (4): 287-92.
7. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 2001; 16 (1): 193-5.
8. Mousa DH, Abdalla AH, Al-Shoail G, et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36 (6): 1831-4.
9. Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18 (11-12): 1071-81.
10. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98 (7): 1610-5.
11. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176 (6): 1614-7.
12. Campistol JM, Esforzado N, Martínez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14 (11): 2704-9.
13. Huraib S, Tanimu D, Romeh SA, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34 (1): 55-60.
14. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 2001; 16 (5): 1017-23.
15. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55 (3): 220-6.
16. Hanrotel C, Toupance O, Lavaud S, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88 (2): 120-6.
17. Glicklich D, Thung SN, Kapoian T, et al. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol 1999; 94 (1): 159-63.
18. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: Characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94 (12): 357-682.
19. Martin P, Carter D, Fabrizi F, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69 (7): 1479-84.
20. Ludwig J. The nomenclature of chronic active hepatitis: An obituary. Gastroenterology 1993; 105 (1): 274-8.
21. Perez RM, Ferraz ML, Figueiredo MS, et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003; 69 (4): 489-94.
22. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339 (21): 1485-92.
23. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352 (9138): 1426-32.
24. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 1998; 9 (12): 2344-8.
25. Uchihara M, Izumi N, Sakai Y, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: Increased serum levels of interferon. Nephron 1998; 80 (1): 51-6.
26. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995; 22 (4 Part 1): 1050-6.
27. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124 (6): 1711-9.
28. Pol S, Vallet-Pichard A, Fontaine H, Lebray P. HCV infection and hemodialysis. Semin Nephrol 2002; 22 (4): 331-9.
29. Barril G, Quiroga JA, Sanz P, et al. Pegylated interferon-alpha2a kinetics during experimental haemodialysis: Impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 2004; 20 (1): 37-44.
30. Teta D, Luscher BL, Gonvers JJ, et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20 (5): 991-3.
31. Lin CC, Philips L, Xu C, Yeh LT. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004; 44 (3): 265-75.